Back to Clinical Trials
Phase 1Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Sponsored by Pierre Fabre Medicament

About this study

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

This is a two-part, open-label, multi-center, dose escalation and dose expansion study in participants with BRAF mutation-positive and/or NRAS mutation-positive tumors designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of KIN-2787, a RAF small molecule kinase inhibitor, to determine a recommended Phase 2 dose (RP2D) of KIN-2787, and to assess the objective response to KIN-2787 therapy alone and in combination with binimetinib, a mitogen-activated protein kinase (MEK) inhibitor. The dose expansion phase (Part B) will assess the safety and efficacy of KIN-2787 at the recommended dose and schedule in patients with cancers that contain BRAF Class I, II or III mutations, including lung cancer, melanoma, and other selected solid tumors.

Where this study is enrolling (14)

Show all 14 locations

  • Mayo Clinic - Florida

    Jacksonville, Florida

    I'm interested

  • Sarah Cannon Research Institute - Florida Cancer Specialists

    Orlando, Florida

    I'm interested

  • Mayo Clinic - Rochester

    Rochester, Minnesota

    I'm interested

  • Atlantic Health

    Morristown, New Jersey

    I'm interested

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

    I'm interested

  • Cleveland Clinic

    Cleveland, Ohio

    Call 216-444-7923

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Sarah Cannon Research Institute-Tennessee Oncology

    Nashville, Tennessee

    Call 1(844) 482-4812

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • MD Anderson

    Houston, Texas

    I'm interested

  • Virginia Cancer Specialists

    Fairfax, Virginia

    I'm interested
Who can participate

Inclusion criteria

  • ✓Provide written informed consent prior to initiation of any study-specific procedures.
  • ✓Metastatic or advanced stage solid tumor
  • ✓Known BRAF Class I, Class II, or Class III alteration or melanoma with an NRAS mutation as confirmed by previous genomic analysis of tumor tissue or ctDNA.
  • ✓Measurable (Part A and B) or evaluable (Part A only) disease by RECIST v1.1.
  • ✓ECOG performance status 0-1
  • ✓Adequate organ function, as measured by laboratory values (criteria listed in protocol).
  • ✓Able to swallow, retain, and absorb oral medications.

Exclusion criteria

  • ✕Known participants who have received local therapy with either surgery and/or radiation therapy (participants with asymptomatic untreated brain metastasis may be eligible if met with certain criteria)
  • ✕In Part B Dose Expansion, previous treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy.
  • ✕GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease.
  • ✕Active, uncontrolled bacterial, fungal, or viral infection.
  • ✕Participant with a positive test result for SARS-CoV2 infection, is known to have asymptomatic infection or is suspected of having SARS-CoV2, is excluded
  • ✕Women who are lactating or breastfeeding, or pregnant.
  • ✕Participants with any other active treated malignancy within 3 years prior to enrollment
  • ✕Complete inclusion and exclusion criteria are listed in the clinical study protocol.

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.